This week marks two significant milestones for Spyre as we celebrate our one-year anniversary and announce the initiation of our first clinical trial evaluating SPY001, an investigational half-life extended anti-α4β7 monoclonal antibody, in healthy volunteers. We are proud of the hard work and dedication that were required to reach this stage and excited about our future with two additional programs expected to enter clinical studies in the next year. Together, we hope these investigational therapies will lead to a meaningful step forward in the treatment of IBD. Learn more: https://lnkd.in/gi-ebw4A #IBD
Keep growing Spyre Therapeutics. More to come
Well done!
Amazing strides
Congratulations Deanna to you and the team!
Congratulations to the Spyre team!
Congratulations!
Well done!
Congratulations!
Congratulations Deanna!
Biotech Executive, Physician Scientist, Chief Medical Officer, Board Member
2wCongratulations Deanna on the great progress!